Vanguard Capital Management’s Castle Biosciences CSTL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$44M Buy
1,237,951
+11,454
+0.9% +$346K ﹤0.01% 1957
2026
Q2
$29.3M Buy
1,226,497
+48,975
+4% +$1.09M ﹤0.01% 2235
2026
Q1
$28.9M Buy
+1,177,522
New +$38.6M ﹤0.01% 2150

Other funds holding CSTL

Vanguard Capital Management's CSTL Position: Q3 2026 in Review

Vanguard Capital Management increased its Castle Biosciences (CSTL) stake by 0.93% in Q3 2026, buying an estimated $346K and bringing the position to 1,237,951 shares worth $44M. The position accounts for ﹤0.01% of the portfolio, ranked #1957.

Vanguard Capital Management first reported a position in CSTL in Q1 2026 and has held it in 3 quarters since. 202 funds tracked by Wall St. Rank hold CSTL as of Q3 2026.

  • Vanguard Capital Management held 1,237,951 shares of Castle Biosciences worth $44M as of Q3 2026.
  • Vanguard Capital Management bought 11,454 Castle Biosciences shares in Q3 2026, an estimated $346K.
  • Castle Biosciences made up ﹤0.01% of Vanguard Capital Management's portfolio in Q3 2026, its #1957 holding.
  • Vanguard Capital Management first reported a position in Castle Biosciences in Q1 2026 and has held it in 3 quarters since.
  • 202 funds tracked by Wall St. Rank held Castle Biosciences as of Q3 2026.

Based on Vanguard Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.